CTLA-4 blockade with ipilimumab improved two-year survival in metastatic uveal melanoma (34% vs. 12% with chemotherapy), but 18% developed non-infectious uveitis requiring steroid-sparing agents like mycophenolate. Here, CTLA4 is linked to uveitis.